Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | OPERA: contact X-ray brachytherapy in addition to CRT in organ preservation for rectal cancer

Jean-Pierre Gerard, MD, Centre Antoine Lacassagne, Nice, France, presents three-year data from the Phase III OPERA trial (NCT02505750), which investigated the efficacy of contact X-ray brachytherapy (CXB) in addition to chemoradiotherapy in organ preservation for rectal adenocarcinoma. 144 patients were recruited and given chemoradiotherapy followed by CXB or external beam radiotherapy (EBRT). At three-year follow-up, CXB with chemoradiotherapy improved the likelihood of organ preservation, especially if the tumor is less than 3cm in diameter. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.